Minireviews
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Mar 27, 2020; 12(3): 85-92
Published online Mar 27, 2020. doi: 10.4240/wjgs.v12.i3.85
Evolution and current status of the subclassification of intermediate hepatocellular carcinoma
Peng-Sheng Yi, Hong Wang, Jian-Shui Li
Peng-Sheng Yi, Jian-Shui Li, Department of Hepato-biliary-pancrease, Affiliated Hospital of North Sichuan Medical College, Nanchong 637000, Sichuan Province, China
Hong Wang, Department of Orthopedics, Affiliated Hospital of Guizhou Medical University, Guiyang 550001, Guizhou Province, China
Author contributions: Li JS proposed the idea; Yi PS and Wang H wrote the paper; Yi PS collected literatures and abstracted data.
Conflict-of-interest statement: No conflict of interest is reported by the authors.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jian-Shui Li, MD, Professor, Department of Hepato-biliary-pancrease, Institute of General surgery, Affiliated Hospital of North Sichuan Medical College, Wenhua Road, No. 63, Nanchong 637000, Sichuan Province, China. 15208207079@163.com
Received: November 11, 2019
Peer-review started: November 11, 2019
First decision: December 11, 2019
Revised: December 21, 2019
Accepted: February 17, 2020
Article in press: February 17, 2020
Published online: March 27, 2020
Processing time: 108 Days and 17 Hours
Core Tip

Core tip: The present study reviewed the literatures and provided a general overview of the evolution and current status of the subclassification of intermediate hepatocellular carcinoma. We propose to expand the indication of liver resection and add radical treatments as the first option of the treatment for patients with intermediate hepatocellular carcinoma.